Announcement on obtaining the Phase I clinical study summary report of STSP-0601 for injection

Staidson (Beijing) Biopharmaceutical Co., Ltd. obtained a clinical research summary report on the phase I clinical trial of STSP-0601 for injection. STSP-0601 for injection is a coagulation factor X activator for the treatment of bleeding in patients with hemophilia A or B with inhibitors.